<DOC>
	<DOCNO>NCT01892514</DOCNO>
	<brief_summary>Femoral head avascular necrosis relatively common disease ( 10,000 - 20,000 yearly new United States America case ) characterize ischemic cell necrosis hip proximal epiphysis area frequently require total Hip Arthroplasty ( THA ) . Even though THA resolve symptom restores good joint function , young patient prone major disability require prosthesis revision surgery . In clinical trial comparison two group patient , treated procedure two different regenerative technique , perform : 1 . 52 patient necrosis early stage , without deformity femoral epiphysis ( stage 2A-B-C Association Research Osseous Circulation ( ARCO ) classification , undergo wide decompression necrotic area reconstruction homologous Lyophilized Bone Chips ( LBC ) , growth factor platelet concentrate Platelet-Rich Fibrin ( PRF ) Concentrated Bone Marrow ( CBM ) . 2 . 52 patient necrosis similar feature , without deformity femoral epiphysis , undergo wide decompression necrotic area reconstruction Demineralized Bone Matrix ( DBM ) , growth factor Platelet-Rich-Fibrin ( PRF ) Concentrated Bone Marrow ( CBM ) . Patients evaluate post-surgery 6 week , 3 , 6 , 12 , 24 month assess joint damage evolution ARCO classification , hip function clinical score ( Harris Hip Score ( HHS ) , Western Ontario McMaster Universities Arthritis Index ( WOMAC ) Score , Visual Analogic Scale ( VAS ) ) .</brief_summary>
	<brief_title>Randomized Clinical Trial Treatment Osteonecrosis Femoral Head</brief_title>
	<detailed_description>Rationale . In vitro study animal model show Mesenchymal Stromal Cells ( MSC ) capacity differentiate osteoblastic lineage platelet reach fibrin represent clinical source growth factor , able accelerate process tissue repair . This study intend highlight factor , associate two different preparation bone allograft , may accelerate formation new host bone patient osteonecrosis femoral head represent common condition clinical practice high socio-economic impact . Primary objective study delay avoid total hip replacement patient early necrosis femoral head , use different method regenerative medicine . Secondary end point describe : - To assess difference outcome related feature , etiology localization necrosis femoral head assess variation post-operative return daily activity . - To characterize osteogenetic angiogenic potential marrow-derived Mesenchymal Stromal Cells ( MSC ) patient avascular necrosis femoral head , correlate feature medical history clinical outcome .</detailed_description>
	<mesh_term>Osteonecrosis</mesh_term>
	<criteria>Patients necrosis femoral head without fracture subchondral bone without flatten head ( accord ARCO classification 2A , B , C ) . Age 18 60 year . Any etiology Patients undergo previous orthopaedic treatment traumatology intervention Patients age 18 year 60 year . Patients able provide informed consent treatment . Patients suffer apparent local infective process . Patients active neoplastic disease . Patients necrosis femoral head advance stage ( ARCO 3A , B , C , 4 ) . Pregnant patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>osteonecrosis</keyword>
	<keyword>bone marrow concentrate</keyword>
	<keyword>demineralize bone matrix</keyword>
	<keyword>homologous lyophilize bone chip</keyword>
	<keyword>autologous platelet rich fibrin</keyword>
	<keyword>mesenchymal stromal cell</keyword>
</DOC>